Chicago Capital LLC Acquires 1,115 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Chicago Capital LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 87,299 shares of the company's stock after acquiring an additional 1,115 shares during the period. Chicago Capital LLC owned 0.11% of IDEXX Laboratories worth $36,661,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Norges Bank purchased a new stake in IDEXX Laboratories during the fourth quarter valued at about $412,258,000. GAMMA Investing LLC increased its position in shares of IDEXX Laboratories by 59,810.7% in the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after purchasing an additional 916,898 shares during the last quarter. Flossbach Von Storch SE increased its holdings in shares of IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after buying an additional 464,791 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in IDEXX Laboratories in the fourth quarter valued at $156,412,000. Finally, William Blair Investment Management LLC increased its position in shares of IDEXX Laboratories by 701.6% during the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock valued at $174,527,000 after purchasing an additional 369,471 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the sale, the director now directly owns 1,801 shares of the company's stock, valued at $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.98% of the company's stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several analyst reports. Leerink Partners lifted their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. Stifel Nicolaus increased their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Finally, Morgan Stanley boosted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $546.00.

IDEXX Laboratories Stock Performance

IDXX stock opened at $528.77 on Tuesday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $530.73. The firm has a market cap of $42.52 billion, a price-to-earnings ratio of 49.56, a PEG ratio of 3.41 and a beta of 1.55. The business's fifty day simple moving average is $476.46 and its two-hundred day simple moving average is $445.36. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same period in the previous year, the company earned $2.71 EPS. The firm's quarterly revenue was up 3.6% on a year-over-year basis. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.